Effectiveness of Duloxetine Monotherapy Compared to Combination Therapy with Other Antidepressants in Patients with Major Depressive Disorder: A Short-Term, Retrospective Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveaaThe purpose of this study was to compare duloxetine monotherapy to combination therapy with other antidepressants in patients with major depressive disorder in a clinical, real world setting. MethodsaaAn eight-week, retrospective, multi-center study of outpatients with major depressive disorder was undertaken. After screening 415 patients, enrolled in this study from July 2009 to June 2014 were 82 patients from among three centers who had been taking duloxetine with or without other antidepressant and not administered with atypical antipsychotics. We compared the mean changes of the Clinical Global Impression-Severity Scale (CGI-S) as a primary measure and the discontinuation rate as a secondary measure between the duloxetine monotherapy group (n=36, 43.9%) and the combination therapy with other antidepressants group (n=46, 56.1%) at baseline, one, two, four and eight weeks. ResultsaaThere were no significant differences across the demographic characteristics between two groups. There was, however, a statistically greater improvement on the CGI-S at weeks 2, 4 and 8 in the combination group compared with the monotherapy group. There were no significant differences in discontinuation rate and adverse events between two groups. No serious adverse events were reported in both groups during the study period. ConclusionaaThis result suggests that the duloxetine combination therapy with other antidepressants could improve effectiveness and have comparable tolerability with the monotherapy in the treatment of outpatients with major depressive disorders in a naturalistic setting. Adequately powered, well-controlled clinical trials are strongly warranted to confirm our findings due to methodological shortcomings.
Abstract
ObjectiveaaThe purpose of this study was to compare duloxetine monotherapy to combination therapy with other antidepressants in patients with major depressive disorder in a clinical, real world setting. MethodsaaAn eight-week, retrospective, multi-center study of outpatients with major depressive disorder was undertaken. After screening 415 patients, enrolled in this study from July 2009 to June 2014 were 82 patients from among three centers who had been taking duloxetine with or without other antidepressant and not administered with atypical antipsychotics. We compared the mean changes of the Clinical Global Impression-Severity Scale (CGI-S) as a primary measure and the discontinuation rate as a secondary measure between the duloxetine monotherapy group (n=36, 43.9%) and the combination therapy with other antidepressants group (n=46, 56.1%) at baseline, one, two, four and eight weeks. ResultsaaThere were no significant differences across the demographic characteristics between two groups. There was, however, a statistically greater improvement on the CGI-S at weeks 2, 4 and 8 in the combination group compared with the monotherapy group. There were no significant differences in discontinuation rate and adverse events between two groups. No serious adverse events were reported in both groups during the study period. ConclusionaaThis result suggests that the duloxetine combination therapy with other antidepressants could improve effectiveness and have comparable tolerability with the monotherapy in the treatment of outpatients with major depressive disorders in a naturalistic setting. Adequately powered, well-controlled clinical trials are strongly warranted to confirm our findings due to methodological shortcomings.
참고문헌 (21)
- Agency for Health Care Policy and Research. Depression in Primary Care, "United States. Depression Guideline Panel", US Deptartment of Health and Human Services, ~ (1993)
- Rush AJ, "Combining medications to enhance depression outcomes(CO-MED) : acute and long-term outcomes of a single-blind randomized study", Am J Psychiatry, 168, pp.689~701 (2011)
- Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
- American Psychiatric Association, "Practice guideline for the treatment of patients with major depressive disorder (revision)", Am J Psychiatry, 157(4 Suppl), pp.1~45 (2000)
- Thase ME, "Antidepressant combinations: widely used, but far from empirically validated", Can J Psychiatry, 56, pp.317~323 (2011)
- Blier P, "Combination of antidepressant medications from treatment initiation for major depressive disorder : a double-blind randomized study", Am J Psychiatry, 167, pp.281~288 (2010)
- Nemeroff CB, "Duloxetine for the treatment of major depressive disorder", Psychopharmacol Bull, 36, pp.106~132 (2002)
- Detke MJ, "Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial", J Clin Psychiatry, 63, pp.308~315 (2002)
- Detke MJ, "Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression", J Psychiatr Res, 36, pp.383~390 (2002)
- Detke MJ, "Duloxetine in the acute and long-term treatment of major depressive disorder : a placebo-and paroxetine-controlled trial", Eur Neuropsychopharmacol, 14, pp.457~470 (2004)
- Goldstein DJ, "Duloxetine in the treatment of major depressive disorder : a double-blind clinical trial", J Clin Psychiatry, 63, pp.225~231 (2002)
- Goldstein DJ, "Duloxetine in the treatment of depression : a double-blind placebo-controlled comparison with paroxetine", J Clin Psychopharmacol, 24, pp.389~399 (2004)
- Perahia DG, "Duloxetine in the prevention of relapse of major depressive disorder : double-blind placebo-controlled study", Br J Psychiatry, 188, pp.346~353 (2006)
- Gartlehner G, "The general and comparative efficacy and safety of duloxetine in major depressive disorder : a systematic review and meta-analysis", Drug Saf, 32, pp.1159~1173 (2009)
- Hudson JI, "Safety and tolerability of duloxetine in the treatment of major depressive disorder : analysis of pooled data from eight placebo-controlled clinical trials", Hum Psychopharmacol, 20, pp.327~341 (2005)
- Diagnostic Criteria from DSM-IV-TR, "American Psychiatric Association", American Psychiatric Association, ~ (2000)
- Busner J, "The clinical global impressions scale : applying a research tool in clinical practice", Psychiatry, 4, pp.28~37 (2007)
- Rocha FL, "Combination of antidepressants in the treatment of major depressive disorder : a systematic review and meta-analysis", J Clin Psychopharmacol, 32, pp.278~281 (2012)
- Rush AJ, "Combining antidepressant medications: a good idea?", Am J Psychiatry, 167, pp.241~243 (2010)
- Thase ME, "Combined antidepressant strategies are not more effective than vigorous escitalopram monotherapy : results of the CO-MED study", Curr Psychiatry Rep, 13, pp.434~436 (2011)
- Fornaro M, "Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial", Eur Neuropsychopharmacol, 24, pp.1269~1278 (2014)